Join the 200th Anniversary Celebration

Original Article

Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction

Anthony H. Gershlick, M.B., B.S., Amanda Stephens-Lloyd, R.N., M.Sc., Sarah Hughes, R.N., B.A., Keith R. Abrams, Ph.D., Suzanne E. Stevens, M.Sc., Neal G. Uren, M.D., Adam de Belder, M.D., John Davis, M.B., B.S., Michael Pitt, M.B., B.S., Adrian Banning, M.D., Andreas Baumbach, M.D., Man Fai Shiu, M.D., Peter Schofield, M.D., Keith D. Dawkins, M.D., Robert A. Henderson, M.D., Keith G. Oldroyd, M.D., and Robert Wilcox, M.D. for the REACT Trial Investigators

N Engl J Med 2005; 353:2758-2768December 29, 2005

Abstract

Background

The appropriate treatment for patients in whom reperfusion fails to occur after thrombolytic therapy for acute myocardial infarction remains unclear. There are few data comparing emergency percutaneous coronary intervention (rescue PCI) with conservative care in such patients, and none comparing rescue PCI with repeated thrombolysis.

Methods

We conducted a multicenter trial in the United Kingdom involving 427 patients with ST-segment elevation myocardial infarction in whom reperfusion failed to occur (less than 50 percent ST-segment resolution) within 90 minutes after thrombolytic treatment. The patients were randomly assigned to repeated thrombolysis (142 patients), conservative treatment (141 patients), or rescue PCI (144 patients). The primary end point was a composite of death, reinfarction, stroke, or severe heart failure within six months.

Results

The rate of event-free survival among patients treated with rescue PCI was 84.6 percent, as compared with 70.1 percent among those receiving conservative therapy and 68.7 percent among those undergoing repeated thrombolysis (overall P=0.004). The adjusted hazard ratio for the occurrence of the primary end point for repeated thrombolysis versus conservative therapy was 1.09 (95 percent confidence interval, 0.71 to 1.67; P=0.69), as compared with adjusted hazard ratios of 0.43 (95 percent confidence interval, 0.26 to 0.72; P=0.001) for rescue PCI versus repeated thrombolysis and 0.47 (95 percent confidence interval, 0.28 to 0.79; P=0.004) for rescue PCI versus conservative therapy. There were no significant differences in mortality from all causes. Nonfatal bleeding, mostly at the sheath-insertion site, was more common with rescue PCI. At six months, 86.2 percent of the rescue-PCI group were free from revascularization, as compared with 77.6 percent of the conservative-therapy group and 74.4 percent of the repeated-thrombolysis group (overall P=0.05).

Conclusions

Event-free survival after failed thrombolytic therapy was significantly higher with rescue PCI than with repeated thrombolysis or conservative treatment. Rescue PCI should be considered for patients in whom reperfusion fails to occur after thrombolytic therapy.

Media in This Article

Figure 1Kaplan–Meier Estimates of the Cumulative Rate of the Composite Primary End Point (Death, Recurrent Myocardial Infarction, Severe Heart Failure, or Cerebrovascular Event) within Six Months.
Figure 2Adjusted Hazard Ratios for the Occurrence of the Composite Primary End Point (Death, Recurrent Myocardial Infarction, Severe Heart Failure, or Cerebrovascular Accident) among the Trial Groups.
Article

Patients who have an open infarct-related artery after acute myocardial infarction with ST-segment elevation have better clinical outcomes than patients without an open artery.1-4 Although primary percutaneous coronary intervention (primary PCI) is a proven therapeutic approach in this setting5,6 and is used increasingly, intravenous thrombolysis remains the first-line therapy in 30 to 70 percent of cases worldwide.7,8 However, thrombolysis results in a grade 3 flow, according to the Thrombolysis in Myocardial Infarction (TIMI) classification system, in only 60 percent of patients, even with current fibrin-specific agents.9 To date, it has been unclear how best to treat the remaining patients, in whom thrombolysis has failed. Some physicians, particularly those at hospitals without interventional facilities, treat such patients conservatively.10 Others believe that a second dose of a thrombolytic agent may be beneficial.11 Many advocate emergency PCI (rescue PCI) on the basis of small trials that have suggested a benefit of this intervention.12,13 The Rescue Angioplasty versus Conservative Treatment or Repeat Thrombolysis (REACT) trial was undertaken to establish which of these three options achieves the best clinical outcome among patients in whom thrombolysis has failed.

Methods

We conducted a multicenter, randomized, parallel-group trial that was approved by United Kingdom national and local ethics committees and fulfilled the conditions of the Declaration of Helsinki. The trial was funded by the British Heart Foundation; Roche Pharmaceuticals provided reteplase for repeated thrombolysis (its use was optional for physician investigators). The sponsors had no role in study design, data collection, or study analysis or in the writing of this report.

Patients

Between December 1999 and March 2004, trial candidates were evaluated at 35 centers (which joined the study on a rolling basis over three years); 19 of the centers had on-site angiographic facilities. Adults 21 to 85 years of age were eligible for inclusion if they had received any licensed thrombolytic agent for myocardial infarction with ST-segment elevation within 6 hours of the onset of chest pain and if reperfusion had then failed to occur, as judged by the predetermined 90-minute electrocardiographic criterion (less than 50 percent resolution in the lead with previous maximal ST-segment elevation). The inclusion and exclusion criteria are listed in Table 1Table 1Criteria for Inclusion and Exclusion and Definitions of Trial End Points.. A screening log of potential subjects was kept through November 2002 to catalogue patients who did or did not participate in the trial; however, this log was not maintained after November 2002 because of funding constraints. The trial subjects were enrolled after giving written informed consent.

Randomization

Patients were randomly assigned by a 24-hour computer-generated random-allocation system to undergo repeated thrombolysis, conservative treatment, or rescue PCI. Patients assigned to repeated thrombolysis received a fibrin-specific thrombolytic agent (alteplase or reteplase, according to the physician's choice) and intravenous heparin, according to standard clinical practice. Low-molecular-weight heparin was not used in the first 24 hours. Patients assigned to the conservative-therapy group received standard medical therapy for myocardial infarction without thrombolysis or PCI. To ensure a standardized group, conservative therapy included intravenous heparin for 24 hours, irrespective of the first thrombolytic agent. Heparin administration in the repeated-thrombolysis and conservative-therapy groups was titrated to an activated partial-thromboplastin time ratio of 1.5 to 2.5. Patients assigned to rescue PCI underwent coronary angiography, proceeding to angioplasty if required (i.e., if the patient had less than TIMI grade 3 flow and more than 50 percent stenosis in the infarct-related artery). Adjunctive strategies (e.g., stenting or glycoprotein IIb/IIIa receptor inhibition) were used at the discretion of the interventionist. Crossover among the three treatment groups was discouraged but was allowed if a patient had ongoing or further chest pain associated with ST-segment re-elevation or new elevation in at least two contiguous leads or had cardiogenic shock.

Data Collection

Clinical examination, electrocardiography, hematologic measurements, and biochemical tests (including measurement of cardiac biomarkers) were performed on all patients 4 hours after the initiation of the randomly assigned therapy (to account for the potential time delay to rescue PCI), at 12 and 24 hours after randomization, and at discharge, with clinical follow-up at 1, 6, and 12 months. The components of the primary end point were continuously documented. More than 90 percent of study data were subjected to source validation according to strictly controlled criteria.

End Points

The primary end point was a composite of major adverse cardiac and cerebrovascular events at six months, including death, recurrent myocardial infarction, cerebrovascular event, and severe heart failure. The secondary end points included the components of the primary end point, as well as bleeding and revascularization. Events were adjudicated by an independent end-point committee, whose members were blinded to treatment assignment. Quality-of-life and resource-use data were collected at follow-up. Definitions of all end points are given in Table 1.

Power and Sample Size

On the basis of the limited evidence available at the time of study design (1998),12 the steering committee estimated that the rate of the primary composite end point in the conservative-therapy group would approach 20 percent and hypothesized a 40 percent relative reduction in this rate in the rescue-PCI group; thus, it was calculated that 1200 patients would be required (80 percent power, α=0.05). In December 2001, the members of the steering committee and the data and safety monitoring committee (who did not have access to the trial data) examined new published evidence suggesting that the rate of death or recurrent myocardial infarction would be 29 percent with conservative therapy, 26.5 percent with repeated thrombolysis, and 15 percent with rescue PCI.11,13-15 Because the rates of heart failure and cerebrovascular events were inconsistently reported in those studies, the power of our study was recalculated on the basis of assumed rates of death and recurrent myocardial infarction alone. It was determined that a sample size of 156 patients in each group would provide 80 percent power (α=0.05) to detect the same 40 percent relative reduction in the composite end point that was previously hypothesized. It was assumed that heart failure and cerebrovascular events would be likely to increase rather than reduce such power in the final analysis.

During 2003 and 2004, enrollment in the trial began to decline. The precise reason for this decline is uncertain, because the screening log was not maintained after November 2002 (as noted above). However, other ongoing clinical trials, as well as the introduction of the new thrombolytic agent tenecteplase (and the concomitant unlicensed use of low-molecular-weight heparin), limited the number of suitable candidates for participation. Because of declining trial recruitment and a finite funding period, the steering committee terminated enrollment in the trial in March 2004.

Statistical Analysis

All analyses were performed on an intention-to-treat basis. Process times are reported as medians with interquartile ranges and compared with use of the Kruskal–Wallis test. The proportions of subjects in each of the groups who reached any end point during the six months were compared with use of either the chi-square test or Fisher's exact test, as appropriate. Survival and event-free survival were plotted as Kaplan–Meier curves, and the log-rank test was used to compare them. Hazard ratios with 95 percent confidence intervals were calculated for all pairwise comparisons. Cox proportional-hazards regression models were used to investigate the potential influence of all baseline covariates on treatment effects. Covariates were selected for a final model by a forward variable-selection procedure. The assumption of proportional hazards was assessed both graphically, with the use of log–log survivor plots, and by adding associated time-dependent covariates to the model.16 There was no evidence that the assumption of proportional hazards was violated in any of the results presented here. No formal adjustment for multiple testing was undertaken, but the P values were interpreted cautiously. All statistical analyses were performed with SAS software, version 8.2 (SAS Institute).

Results

At the termination of the trial, 435 patients had been enrolled and randomly assigned to one of the three treatment groups. Of these, six withdrew consent (one each in the groups assigned to repeated thrombolysis and rescue PCI and four in the group assigned to conservative therapy), and another two were excluded (one each in the repeated-thrombolysis and rescue-PCI groups) because they had inappropriately undergone randomization before giving consent, which they declined to do. The data for 427 patients are therefore presented. Of these, 142 were assigned to repeated thrombolysis, 141 to conservative therapy, and 144 to rescue PCI (Table 2Table 2Baseline Characteristics of Enrolled Patients.).

The trial screening log, which was maintained until November 2002, included 713 patients who did not undergo randomization (as compared with 304 patients who had undergone randomization by that date). Of those who did not undergo randomization, most were excluded on the basis of clinical criteria, including delayed presentation (beyond six hours) (24 percent), advanced age (21.4 percent), and severe hypertension (13.6 percent). Only 4.2 percent were excluded on the basis of the judgment of the patient's physician.

Baseline Characteristics

The baseline characteristics were similar in all groups (Table 2). There was no difference among the groups in the median time from the onset of pain to the first (nontrial) thrombolytic treatment (P=0.73). The median time from presentation until the first thrombolytic treatment (“door-to-needle time”) was 27 minutes (interquartile range, 16 to 43).

Actual Treatment Received

Eighteen patients (4.2 percent) did not receive their randomly assigned treatment. Among the patients who were assigned to rescue PCI, 14 received conservative therapy and 2 received repeated thrombolysis; among the patients who were assigned to repeated thrombolysis, 1 received conservative therapy and 1 received rescue PCI. The results of the analysis according to the intention-to-treat principle were unchanged when the data were analyzed according to actual treatment received.

Rescue Pci

Of the 144 patients assigned to rescue PCI, 88 (61.1 percent) were recruited from hospitals with interventional capabilities. The median transfer time for patients from hospitals without interventional capabilities was 85 minutes (interquartile range, 55 to 120). Sixteen patients in this group crossed from their assigned therapy, and 128 proceeded to angiography, 13 of whom did not require angioplasty because of patent vessels. Of the remaining 115 patients, only 9 were deemed to have had an unsuccessful rescue-PCI procedure; in 6 of these patients the artery was deemed not amenable to PCI, in one instance affecting 1 patient there was a technical failure of x-ray equipment, and in 2 patients the attempts to open the artery were unsuccessful.

Rescue PCI was commenced (i.e., the wire crossed the lesion) a median of 414 minutes after the onset of pain (interquartile range, 350 to 505). Stents were deployed in 68.5 percent of patients, and a glycoprotein IIb/IIIa receptor inhibitor (abciximab) was administered in 43.4 percent. For patients assigned to rescue PCI rather than repeated thrombolysis, the median additional delay in the time to the assigned treatment was 84 minutes (4.6 hours for rescue PCI vs. 3.2 hours for repeated thrombolysis).

Primary End Point

All components of the primary end point were recorded for 406 subjects (95.1 percent). Mortality status was confirmed for the remaining 21 subjects (4.9 percent): 6 each in the repeated-thrombolysis and conservative-therapy groups and 9 in the rescue PCI-group. Data on these subjects were included in the analyses as censored observations, with a median study period of 105 days (range, 5 to 177).

In the rescue-PCI group, 15.3 percent of the patients reached at least one component of the primary end point, as compared with 31.0 percent in the repeated-thrombolysis group and 29.8 percent in the conservative-therapy group (overall P=0.003) (Table 3Table 3End-Point Events Occurring within Six Months of Treatment.). The rate of event-free survival (Figure 1Figure 1Kaplan–Meier Estimates of the Cumulative Rate of the Composite Primary End Point (Death, Recurrent Myocardial Infarction, Severe Heart Failure, or Cerebrovascular Event) within Six Months.) was 84.6 percent in the rescue-PCI group, as compared with 70.1 percent in the conservative-therapy group and 68.7 percent in the repeated-thrombolysis group (overall P=0.004). Among patients assigned to rescue PCI, there was no significant difference in event rates between those who were transferred for intervention (16.4 percent) and those who were recruited in hospitals with on-site facilities for intervention (14.6 percent, P=0.80), and logistic-regression analysis indicated that the time to repeated PCI (up to 12 hours) had no significant effect on outcome. Although the numbers are very small, the incidence of the primary end point was much higher among those who underwent unsuccessful rescue PCI (5 of 9 patients [55.6 percent]) than among those who underwent successful rescue PCI (12 of 106 patients [11.3 percent], P=0.007).

Age and infarct site were the only baseline characteristics that were identified as predictors of the primary end point by multivariate analysis. Adjusted pairwise hazard ratios (Figure 2Figure 2Adjusted Hazard Ratios for the Occurrence of the Composite Primary End Point (Death, Recurrent Myocardial Infarction, Severe Heart Failure, or Cerebrovascular Accident) among the Trial Groups.) confirmed a statistically significant benefit of rescue PCI as compared with conservative therapy (hazard ratio, 0.47; 95 percent confidence interval, 0.28 to 0.79; P=0.004) and repeated thrombolysis (hazard ratio, 0.43; 95 percent confidence interval, 0.26 to 0.72; P=0.001). There was no significant difference in benefit between repeated thrombolysis and conservative therapy (hazard ratio, 1.09; 95 percent confidence interval, 0.71 to 1.67; P=0.69).

Components of the Primary End Point

There was a trend toward lower mortality at six months in the rescue-PCI group (6.2 percent) than in either the repeated-thrombolysis group (12.7 percent) or the conservative-therapy group (12.8 percent, P=0.12 for both comparisons) (Table 3). When the rescue-PCI group was compared with the two other groups combined, this difference was statistically significant (hazard ratio, 0.48; 95 percent confidence interval, 0.23 to 0.99; P<0.05). Multivariate analysis identified age and diabetes as significant predictors of death, and the adjusted hazard ratios significantly favored rescue PCI: the hazard ratio for rescue PCI as compared with repeated thrombolysis was 0.42 (95 percent confidence interval, 0.19 to 0.94; P<0.04), and the hazard ratio for rescue PCI as compared with conservative therapy was 0.42 (95 percent confidence interval, 0.19 to 0.94; P<0.04). The trial was not powered to detect a difference in mortality alone.

There were no significant differences in the rates of cerebrovascular events or severe heart failure among the three treatment groups (Table 3). However, the rate of recurrent myocardial infarction was significantly lower in the rescue-PCI group (2.1 percent) than in the repeated-thrombolysis group (10.6 percent) or the conservative-therapy group (8.5 percent); the hazard ratio for rescue PCI as compared with repeated thrombolysis was 0.23 (95 percent confidence interval, 0.09 to 0.62; P=0.004), and the hazard ratio for rescue PCI as compared with conservative therapy was 0.33 (95 percent confidence interval, 0.12 to 0.93; P=0.04).

Bleeding Complications

Bleeding events were defined according to a modified TIMI classification (Table 1).17 There were no significant differences among the groups in major bleeding events (Table 3). However, there was a tendency toward higher mortality from major bleeding episodes in the repeated-thrombolysis group (four deaths from hemopericardium and one death from intracranial hemorrhage) and the conservative-therapy group (one death from hemothorax and two deaths from intracranial hemorrhage) than in the rescue-PCI group, in which there were no deaths associated with bleeding events. Minor bleeding episodes were significantly more frequent in the rescue-PCI group (P<0.001); minor bleeding occurred at the access site in 28 patients, 5 of whom required blood transfusion. Among the patients in the rescue-PCI group who had bleeding events, 69 percent had received abciximab, as compared with 43 percent of all patients in this group (P=0.17). There were no significant differences among the groups in the incidence of bleeding episodes characterized by a fall in hemoglobin without an identified bleeding site.

Revascularization

Revascularization rates tended to be lower in the rescue-PCI group (Table 3). At six months, 86.2 percent of the patients in the rescue-PCI group were free from revascularization, as compared with 77.6 percent of those undergoing conservative therapy and 74.4 percent of those undergoing repeated thrombolysis (overall P=0.05 by the log-rank test). The unadjusted hazard ratio for revascularization was 0.50 (95 percent confidence interval, 0.29 to 0.88; P<0.02) for rescue PCI as compared with repeated thrombolysis and 0.58 (95 percent confidence interval, 0.33 to 1.04; P<0.07) for rescue PCI as compared with conservative therapy. There was no difference between the two groups not assigned to rescue PCI (hazard ratio for repeated thrombolysis as compared with conservative therapy, 1.17; 95 percent confidence interval, 0.71 to 1.92; P=0.56).

Discussion

Our study compared three therapeutic options after failed thrombolytic therapy. We found that rescue PCI was superior to either conservative care or repeated thrombolysis, even though a substantial proportion of patients treated with rescue PCI were transferred from hospitals without interventional facilities, and there was a median additional time delay of 84 minutes until treatment with rescue PCI in comparison with repeated thrombolysis. A trend toward a higher frequency of fatal bleeding was noted in both the conservative-treatment group and the repeated-thrombolysis group, but given the small number of cases reported, no firm conclusions can be drawn from these data. The higher rates of nonfatal bleeding in the rescue-PCI group may be due to the use of glycoprotein IIb/IIIa receptor inhibitors.

Previous evidence supporting the use of rescue PCI is limited, and current guidelines recommend it only for certain high-risk subgroups of patients.18,19 Rescue PCI has been reported to lower the rate of recurrent myocardial infarction, reduce the incidence of early severe heart failure, and improve one-year survival.12,15 However, the sample sizes in most studies have been small; moreover, failed rescue PCI has been associated with a high incidence of adverse outcomes (approximately 30 percent),14,20 a result that could reduce the overall benefit of the technique.21,22 The recent use of stents and glycoprotein IIb/IIIa receptor inhibitors may have improved outcomes in comparison with those in studies performed in the mid-1990s.

The findings of our study favoring the use of rescue PCI contradict those of the recent Middlesbrough Early Vascularization to Limit Infarction (MERLIN) trial,23 which found a significant reduction in revascularization rates only. There are a number of important differences between the two trials. The MERLIN trial was a locally confined study, whereas ours was a national multicenter trial. In the MERLIN trial, the first thrombolytic agent was more often streptokinase (96 percent, vs. 59 percent in our trial), and eligibility was determined on the basis of electrocardiography at 60 minutes, rather than 90. This strategy may have reduced the rates of the end points in the conservative-treatment group, since some patients treated with streptokinase probably underwent perfusion at 60 to 90 minutes (as suggested by the fact that 40 percent of the patients in the rescue-PCI group had TIMI grade 3 flow according to angiography before intervention). The MERLIN trial also showed lower rates of stenting and of glycoprotein IIb/IIIa inhibitor use, which may have contributed to a higher reinfarction rate in the rescue-PCI group. For reasons that remain unexplained, the mortality in the rescue-PCI group was unusually high in the MERLIN trial,20 as was the rate of cerebrovascular events in this group (4.6 percent). In addition, despite the absence of a group randomly assigned to repeated thrombolytic treatment, 11.7 percent of the conservatively treated patients in the MERLIN trial underwent repeated thrombolysis, further confounding the results.

The optimal approach for detecting the failure of thrombolytic therapy has been the subject of much debate.24,25 Historically, entry into studies of rescue PCI has been determined by angiographic findings,13,26 whereas in clinical practice, failure of reperfusion is generally detected by clinical, noninvasive markers. There is evidence that the ratios of biochemical markers (including creatine kinase MB fraction, troponin, and myoglobin mass) measured before and 60 minutes after the administration of thrombolytic therapy have good predictive value,27,28 with low ratios correlating with poor patency. However, differential degrees of ST-segment resolution also correlate well with TIMI flow grade29-31 and predict longer-term outcome.32 The value of ongoing pain as a sensitive marker of nonreperfusion is questionable, given its low specificity33 and the routine use of analgesia. Although certain markers (e.g., myoglobin) may be considered the most sensitive for detecting failed thrombolytic therapy, these were not widely available in the clinical setting when our trial was designed. Therefore, an ST-segment resolution of 50 percent was considered the most reliable possible entry criterion, and this cutoff was deemed likely to pick up most reperfusion failures, with a low rate of false positives for patent arteries.30,32,34

Although the trial was terminated early, termination occurred before the investigators were unblinded to the data and was necessary, given the falling recruitment rates and the finite funding period for the study. In the absence of a full registry, we cannot exclude some element of selection bias in the population enrolled. However, all consecutive patients at each site in whom thrombolytic therapy had failed were evaluated, and the baseline characteristics as recorded in the screening log until November 2002 do not suggest such bias. The great majority of patients, according to this record, were excluded for predefined clinical reasons, with only 4.2 percent being excluded by choice of the patient's physician.

In conclusion, the trial found that rescue PCI after failed thrombolytic treatment was associated with a statistically significant reduction in the incidence of major adverse cardiac and cerebrovascular events, as compared with either repeated thrombolysis or conservative management. These results indicate that rescue PCI, with transfer to a tertiary site if required, should be considered for patients in whom thrombolysis for myocardial infarction with ST-segment elevation fails to achieve reperfusion.

Dr. Gershlick reports having served as a consultant to and received lecture fees from Cordis, Boston Scientific, and Medtronic and being currently in receipt of research grant support from Medtronic; Dr. Baumbach, having served as a consultant to Boston Scientific; Dr. Schofield, having served as a consultant to Cordis and Guidant; and Dr. Dawkins, having served as a consultant to Eli Lilly, Boston Scientific, Guidant, and Conor Medsystems, having received lecture fees from Eli Lilly, Boston Scientific, and Guidant, and having appeared as an expert witness for Boston Scientific. No other potential conflict of interest relevant to this article was reported.

We are indebted to Leslie Shortt for data entry, and to the nursing and medical staff of the cardiac care units and catheter laboratories at all sites.

Source Information

From the Department of Cardiology, University Hospitals of Leicester, Leicester (A.H.G., A.S.-L., S.H.); the Departments of Health Sciences (K.R.A.) and Cardiovascular Sciences (S.E.S.), University of Leicester, Leicester; the Department of Cardiology, Royal Infirmary Edinburgh, Edinburgh (N.G.U.); Sussex Cardiac Centre, Royal Sussex County Hospital, Brighton (A. de Belder); the Department of Cardiology, North Staffordshire Hospital, Stoke-on-Trent (J.D.); the Department of Cardiology, Heartlands Hospital, Birmingham (M.P.); the Department of Cardiology, John Radcliffe Hospital, Oxford (A. Banning); the Department of Cardiology, Bristol Royal Infirmary, Bristol (A. Baumbach); the Department of Cardiology, Walsgrave Hospital, Coventry (M.F.S.); the Department of Cardiology, Papworth Hospital, Cambridge (P.S.); Wessex Cardiac Unit, Southampton General Hospital, Southampton (K.D.D.); Trent Cardiac Centre, Nottingham City Hospital, Nottingham (R.A.H.); the Department of Cardiology, Western Infirmary, Glasgow (K.G.O.); and the Department of Cardiovascular Medicine, Queens Medical Centre, Nottingham (R.W.) — all in the United Kingdom.

Address reprint requests to Dr. Gershlick at the University Hospitals of Leicester, Groby St., Leicester LE3 9QP, United Kingdom, or at .

The participants in the Rescue Angioplasty versus Conservative Treatment or Repeat Thrombolysis (REACT) trial are listed in the Appendix.

Appendix

The members of the REACT trial were as follows: Steering Committee — A.H. Gershlick (principal investigator), M. de Belder, H. Swanton, R. Wilcox, K. Abrams, D. de Bono (deceased), and A. Stephens-Lloyd; Data and Safety Committee — K. Fox, J. Birkhead, and M. Bland; End-Point Committee — J. Hampton and S. Davies; Trial coordinators — A. Stephens-Lloyd and S. Hughes; Statisticians — S. Stevens, K. Abrams, and A. Skene; Economic evaluation — M. Buxton and M. Dyer; Investigators, interventionists, and study-site coordinators — Glenfield Hospital, Leicester: J.D. Skehan, J. Kovac, N.J. Samani, and P.J.B. Hubner; Leicester Royal Infirmary, Leicester: I. Squire, L. Shipley, and E. Parker; Leicester General Hospital, Leicester: I. Hudson, R. Pathmanathan, and K. Fairbrother; Royal Infirmary of Edinburgh, Edinburgh: N.G. Uren, D.E. Newby, P. Bloomfield, N.A. Boon, A.D. Flapan, L. Flint, M. O'Donnell, and L. Cameron; Royal Sussex County Hospital, Brighton: A. de Belder, S. Holmberg, D. Hildick-Smith, N. Cooter, and L. Bennett; North Staffordshire Hospital, Stoke-on-Trent: J. Davis, J. Nolan, J. Creamer, D. O'Gorman, J. Machin, and C. Butler; Heartlands Hospital, Birmingham: M. Pitt, P. Ludman, G. Murray, J. Beattie, S. Eccleshall, N. El-Gaylani, J. Pitt, and J. Hulse; Hull Royal Infirmary, Hull: M. Norell, F. Alamgir, J. Caplin, G. Kaye, A. Clark, M. Nasir, J. Bristow, A. Fussey, E. Owen, and A. Baksh; John Radcliffe Hospital, Oxford: A. Banning, N. Alp, H. McCullough, N. Meldrum, C. Hamer, and R. Douthwaite; Bristol Royal Infirmary, Bristol: A. Baumbach, G. Dalton, and K. Carson; Walsgrave Hospital, Coventry: M.F. Shiu, H. Singh, M. Been, P. Glennon, S. Constantinides, and L. Gill; Hairmyres Hospital, East Kilbride: K. Oldroyd, B.D. Vallance, J. Young, and G. Moreland; Papworth Hospital, Cambridge: P. Schofield, M.C. Petch, L.M. Shapiro, S.C. Clarke, H. Millington, A. Emerton, and C. Rhydwen; Southampton General Hospital, Southampton: K. Dawkins, I. Simpson, H. Gray, A. Calver, J. Morgan, Z. Nicholas, and S. Kitt; Addenbrookes Hospital, Cambridge: P. Weissberg, S. Blackwood; Nottingham City Hospital, Nottingham: R. Henderson, D. Falcon-Lang, and M. Marriott; University Hospital of Wales, Cardiff: W. Penny and L. Davies; Royal Devon and Exeter Hospital, Exeter: B. Smith, M. Gandhi, J. Dean, C. Rinaldi, A. Renouf, D. Taylor, and J. Hunt; Royal Surrey County Hospital, Guildford: E. Leatham, R. Mitra, S. Green, and M. Eaton; Wishaw General Hospital, Wishaw, Larnarkshire: M. Malekian and A. Sloey; Derby Royal Infirmary, Derby: M. Millar-Craig and A. Joy; St. Thomas' Hospital, London: S. Redwood, S. Patel, and S. Hogun; Epsom General Hospital, Epsom: S. Odemuyiwa, A. Redwood, and C. Cooper; Southmead Hospital, Bristol: P. Walker, K. Potts, and D. Foster-Hargreaves; West Suffolk Hospital, Bury-St-Edmunds: E. Lee and S. Reader; Western Infirmary, Glasgow: K. Oldroyd, S. Robb, W. Hillis, and J. Kelly; Crosshouse Hospital, Kilmarnock: D. O'Neill and O. El-Wassief; Manchester Heart Centre, Manchester: N. Curzen, F. Fath-Ordoubadi, L. Neyses, and H. Iles-Smith; Royal Alexandra Hospital, Paisley: S. Hood, I. Findlay, and J. Dougall; Hemel Hempstead General Hospital, Hemel Hempstead: D. Hackett and L. Birkhead; Kent and Sussex Hospital, Tunbridge Wells: C. Lawson and J. Highland; Middlesex Hospital, London: H. Swanton and E. Firmin; St. Mary's Hospital, London: R. Foale, J. Mayet, S. Smart, and J. Varghese.

References

References

  1. 1

    The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622[Erratum, N Engl J Med 1994;330:516.]
    Full Text | Web of Science | Medline

  2. 2

    Puma JA, Sketch MH Jr, Thompson TD, et al. Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol 1999;83:482-487
    CrossRef | Web of Science | Medline

  3. 3

    Fath-Ordoubadi F, Huehns TY, Al-Mohammad A, Beatt KJ. Significance of the Thrombolysis in Myocardial Infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. Am Heart J 1997;134:62-68
    CrossRef | Web of Science | Medline

  4. 4

    French JK, Hyde TA, Patel H, et al. Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol 1999;34:62-69
    CrossRef | Web of Science | Medline

  5. 5

    Budaj A, Brieger D, Steg PG, et al. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2003;146:999-1006
    CrossRef | Web of Science | Medline

  6. 6

    Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20
    CrossRef | Web of Science | Medline

  7. 7

    Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-377
    CrossRef | Web of Science | Medline

  8. 8

    The Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322[Erratum, Lancet 1994;343:742.]
    Web of Science | Medline

  9. 9

    Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998;98:2805-2814
    Web of Science | Medline

  10. 10

    Prendergast BD, Shandall A, Buchalter MB. What do we do when thrombolysis fails? A United Kingdom survey. Int J Cardiol 1997;61:39-42
    CrossRef | Web of Science | Medline

  11. 11

    Sarullo FM, Americo L, Di Pasquale P, Castello A, Mauri F. Efficacy of rescue thrombolysis in patients with acute myocardial infarction: preliminary findings. Cardiovasc Drugs Ther 2000;14:83-89
    CrossRef | Web of Science | Medline

  12. 12

    Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994;90:2280-2284
    Web of Science | Medline

  13. 13

    Ross AM, Lundergan CF, Rohrbeck SC, et al. Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. J Am Coll Cardiol 1998;31:1511-1517
    CrossRef | Web of Science | Medline

  14. 14

    Sutton AG, Campbell PG, Grech ED, et al. Failure of thrombolysis: experience with a policy of early angiography and rescue angioplasty for electrocardiographic evidence of failed thrombolysis. Heart 2000;84:197-204
    CrossRef | Web of Science | Medline

  15. 15

    Ellis SG, Da Silva ER, Spaulding CM, Nobuyoshi M, Weiner B, Talley JD. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am Heart J 2000;139:1046-1053
    CrossRef | Web of Science | Medline

  16. 16

    Parmar MKB, Machin D. Survival analysis: a practical approach. Chichester, England: John Wiley, 1995.

  17. 17

    Bovill EG, Tracy RP, Knatterud GL, et al. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol 1997;79:391-396
    CrossRef | Web of Science | Medline

  18. 18

    Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004;44:E1-E211
    CrossRef | Medline

  19. 19

    Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66
    CrossRef | Web of Science | Medline

  20. 20

    Bar FW, Ophnis TJ, Frederiks J, et al. Rescue PTCA following failed thrombolysis and primary PTCA: a retrospective study of angiographic and clinical outcome. J Thromb Thrombolysis 1997;4:281-288
    CrossRef | Medline

  21. 21

    Gibson CM, Cannon CP, Greene RM, et al. Rescue angioplasty in the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. Am J Cardiol 1997;80:21-26
    CrossRef | Web of Science | Medline

  22. 22

    McKendall GR, Forman S, Sopko G, Braunwald E, Williams DO. Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 1995;76:1108-1111
    Web of Science | Medline

  23. 23

    Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004;44:287-296
    CrossRef | Web of Science | Medline

  24. 24

    de Lemos JA, Morrow DA, Gibson CM, et al. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol 2001;88:353-358
    CrossRef | Web of Science | Medline

  25. 25

    Lavin F, Kane M, Forde A, Gannon F, Daly K. Comparison of five cardiac markers in the detection of reperfusion after thrombolysis in acute myocardial infarction. Br Heart J 1995;73:422-427
    CrossRef | Web of Science | Medline

  26. 26

    el Deeb F, Ciampricotti R, el Gamal M, Michels R, Bonnier H, Van Gelder B. Value of immediate angioplasty after intravenous streptokinase in acute myocardial infarction. Am Heart J 1990;119:786-791
    CrossRef | Web of Science | Medline

  27. 27

    Stewart JT, French JK, Theroux P, et al. Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 1998;31:1499-1505
    CrossRef | Web of Science | Medline

  28. 28

    Tanasijevic MJ, Cannon CP, Antman EM, et al. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol 1999;34:739-747
    CrossRef | Web of Science | Medline

  29. 29

    Fernandez AR, Sequeira RF, Chakko S, et al. ST segment tracking for rapid determination of patency of the infarct-related artery in acute myocardial infarction. J Am Coll Cardiol 1995;26:675-683
    CrossRef | Web of Science | Medline

  30. 30

    Zeymer U, Schroder R, Tebbe U, Molhoek GP, Wegscheider K, Neuhaus KL. Non-invasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction: results of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial. Eur Heart J 2001;22:769-775
    CrossRef | Web of Science | Medline

  31. 31

    Gibson CM, Karha J, Giugliano RP, et al. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am Heart J 2004;147:847-852
    CrossRef | Web of Science | Medline

  32. 32

    Schroder R, Wegscheider K, Schroder K, Dissmann R, Meyer-Sabellek W. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens: a substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 1995;26:1657-1664
    CrossRef | Web of Science | Medline

  33. 33

    Christenson RH, Ohman EM, Topol EJ, et al. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. Circulation 1997;96:1776-1782
    CrossRef | Web of Science | Medline

  34. 34

    Andrews J, Straznicky IT, French JK, et al. ST-segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. Circulation 2000;101:2138-2143
    Web of Science | Medline

Citing Articles (124)

Citing Articles

  1. 1

    2012. References. , 348-358.
    CrossRef

  2. 2

    Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
    CrossRef

  3. 3

    S. Dharma, D. A. Juzar, I. Firdaus, S. Soerianata, A. J. Wardeh, J. W. Jukema. (2012) Acute myocardial infarction system of care in the third world. Netherlands Heart Journal
    CrossRef

  4. 4

    Konstantinos Dimopoulos, Dariusz Dudek, Federico Piscione, Waldemar Mielecki, Stefano Savonitto, Francesco Borgia, Ernesto Murena, Antonio Manari, Achille Gaspardone, Andrzej Ochala, Krzysztof Zmudka, Leonardo Bolognese, Philippe Gabriel Steg, Marcus Flather, Carlo Di Mario. (2012) Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: Implications on optimisation of timing of treatment from the CARESS-in-AMI trial. International Journal of Cardiology 154:3, 275-281
    CrossRef

  5. 5

    Juan M. Ruiz-Nodar, Eloísa Feliu, Jessica Sánchez-Quiñones, José Valencia-Martín, Milagros García, Javier Pineda, Patricia Martín, Vicente Mainar, Pascual Bordes, Santiago Heras, Maria A. Quintanilla, Francisco Sogorb. (2011) Minimum Salvaged Myocardium After Rescue Percutaneous Coronary Intervention: Quantification by Cardiac Magnetic Resonance. Revista Española de Cardiología (English Edition) 64:11, 965-971
    CrossRef

  6. 6

    Andrew G.C. Sutton. (2011) Fármacos antiguos e intervención tardía. ¿Podemos mejorar mientras continúa la lucha por el uso universal de la intervención coronaria percutánea?. Revista Española de Cardiología 64:11, 955-958
    CrossRef

  7. 7

    Juan M. Ruiz-Nodar, Eloísa Feliu, Jessica Sánchez-Quiñones, José Valencia-Martín, Milagros García, Javier Pineda, Patricia Martín, Vicente Mainar, Pascual Bordes, Santiago Heras, María A. Quintanilla, Francisco Sogorb. (2011) Miocardio rescatado tras angioplastia coronaria de rescate: cuantificación mediante resonancia magnética cardiaca. Revista Española de Cardiología 64:11, 965-971
    CrossRef

  8. 8

    Andrew G.C. Sutton. (2011) Old Drugs and Late Intervention – Can We Improve as the Struggle for Universal Primary Percutaneous Coronary Intervention Continues?. Revista Española de Cardiología (English Edition) 64:11, 955-958
    CrossRef

  9. 9

    David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. Canadian Journal of Cardiology 27:6, S402-S412
    CrossRef

  10. 10

    Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology
    CrossRef

  11. 11

    Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology
    CrossRef

  12. 12

    Francesco De Felice, Rosario Fiorilli, Antonio Parma, Carmine Musto, Marco Stefano Nazzaro, Pierpaolo Confessore, Massimiliano Scappaticci, Alberta Cifarelli, Roberto Violini. (2011) Comparison of One-Year Outcome of Patients Aged <75 Years Versus ≥75 Years Undergoing “Rescue” Percutaneous Coronary Intervention. The American Journal of Cardiology 108:8, 1075-1080
    CrossRef

  13. 13

    Wolfgang Scheidt, Christian Thilo. (2011) As time goes by? The fallacy of thrombolysis in STEMI networks. Clinical Research in Cardiology 100:10, 867-877
    CrossRef

  14. 14

    Thomas Cuisset, Mathieu Pankert, Jacques Quilici. (2011) Synergy between pharmacological and mechanical reperfusion in ST-segment elevation myocardial infarction patients. Journal of Cardiovascular Medicine1
    CrossRef

  15. 15

    Julien Rosencher, Vanina Bongard, Karim Tazarourte, Louis Soulat, Dominique Savary, Meyer Elbaz, Darko Miljkovic, Yves Cottin, Yves Lambert, Ph. Gabriel Steg, Jacques Puel, Sandrine Charpentier. (2011) A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis. EuroIntervention 7:2, 248-255
    CrossRef

  16. 16

    Francesco De Felice, Rosario Fiorilli, Antonio Parma, Carmine Musto, Marco Stefano Nazzaro, Pierpaolo Confessore, Massimiliano Scappaticci, Roberto Violini. (2011) One-year clinical outcome of patients treated with or without abciximab in rescue coronary angioplasty. International Journal of Cardiology
    CrossRef

  17. 17

    Dennis T. Ko, Clare L. Atzema, Linda R. Donovan, Michelle M. Graham, Thao Huynh, Derek Y. So, Julie Wang, Harindra C. Wijeysundera, Jack V. Tu. (2011) Rescue percutaneous coronary interventions for failed fibrinolytic therapy in ST-segment elevation myocardial infarction: A population-based study. American Heart Journal 161:4, 764-770.e1
    CrossRef

  18. 18

    Antonio Reina Toral, Bernardino Maza Rodríguez, Francisco Manzano Manzano. (2011) ¿Cuál es el escenario actual de la reperfusión en el tratamiento del infarto agudo de miocardio con elevación del ST?. Cardiocore 46:2, 49-52
    CrossRef

  19. 19

    Manav Sohal, Fred Foo, Alex Sirker, Ronak Rajani, Muhammed Z. Khawaja, Nicholas Pegge, Robert Hatrick, Barry Kneale, Mark Signy, Stephen Holmberg, Adam de Belder, David Hildick-Smith. (2011) Rescue angioplasty for failed fibrinolysis-Long-term follow-up of a large cohort. Catheterization and Cardiovascular Interventions 77:5, 599-604
    CrossRef

  20. 20

    Philippe Kolh, William Wijns. (2011) Joint ESC/EACTS guidelines on myocardial revascularization. Journal of Cardiovascular Medicine 12:4, 264-267
    CrossRef

  21. 21

    PATRICIO PÉREZ-BERBEL, JOSÉ VALENCIA, JUAN MIGUEL RUIZ-NODAR, JAVIER PINEDA, PASCUAL BORDES, VICENTE MAINAR, FRANCISCO SOGORB. (2011) Rescue Angioplasty: Characteristics and Results in a Single-Center Experience. Journal of Interventional Cardiology 24:1, 42-48
    CrossRef

  22. 22

    Peter Bogaty, Kristian B Filion, James M Brophy. (2011) Routine invasive management after fibrinolysis in patients with ST-elevation myocardial infarction: a systematic review of randomized clinical trials. BMC Cardiovascular Disorders 11:1, 34
    CrossRef

  23. 23

    Vicente Peral, Andrés Carrillo, Armando Bethencourt, Miguel Fiol, Alfredo Gómez-Jaume, Mar Alameda, Marcos Pascual, Carlos Fernández-Palomeque, Catalina Rubert, Lorenzo Socías. (2011) Modelo de intervención coronaria percutánea primaria en las Islas Baleares. Revista Española de Cardiología Suplementos 11, 35-43
    CrossRef

  24. 24

    Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
    CrossRef

  25. 25

    P. Aubry, X. Halna du Fretay. (2010) Traitements antithrombotiques du syndrome coronarien aigu avec sus-décalage ST. Annales de Cardiologie et d'Angéiologie 59:6, 335-343
    CrossRef

  26. 26

    V. Wenzel, S.G. Russo, H.R. Arntz, J. Bahr, M.A. Baubin, B.W. Böttiger, B. Dirks, U. Kreimeier, M. Fries, C. Eich. (2010) Kommentar zu den Leitlinien 2010 zur kardiopulmonalen Reanimation des European Resuscitation Council. Der Anaesthesist 59:12, 1105-1123
    CrossRef

  27. 27

    Cheuk-Kit Wong, Sophia Leon de la Barra, Peter Herbison. (2010) Does ST resolution achieved via different reperfusion strategies (fibrinolysis vs percutaneous coronary intervention) have different prognostic meaning in ST-elevation myocardial infarction? A systematic review. American Heart Journal 160:5, 842-848.e2
    CrossRef

  28. 28

    Ansar Hassan, Alice Newman, Dennis T. Ko, Stéphane Rinfret, Gregory Hirsch, William A. Ghali, Jack V. Tu. (2010) Increasing rates of angioplasty versus bypass surgery in Canada, 1994-2005. American Heart Journal 160:5, 958-965
    CrossRef

  29. 29

    H.-R. Arntz, L.L. Bossaert, N. Danchin, N. Nicolau. (2010) Initiales Management des akuten Koronarsyndroms. Notfall + Rettungsmedizin 13:7, 621-634
    CrossRef

  30. 30

    , , W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, J. Knuuti, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M. F. Piepoli, C. Pirlet, J. L. Pomar, N. Reifart, F. L. Ribichini, M. J. Schalij, P. Sergeant, P. W. Serruys, S. Silber, M. Sousa Uva, D. Taggart, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. Kolh, O. Alfieri, J. Dunning, S. Elia, P. Kappetein, U. Lockowandt, G. Sarris, P. Vouhe, , P. Kearney, L. von Segesser, S. Agewall, A. Aladashvili, D. Alexopoulos, M. J. Antunes, E. Atalar, A. Brutel de la Riviere, A. Doganov, J. Eha, J. Fajadet, R. Ferreira, J. Garot, J. Halcox, Y. Hasin, S. Janssens, K. Kervinen, G. Laufer, V. Legrand, S. A. M. Nashef, F.-J. Neumann, K. Niemela, P. Nihoyannopoulos, M. Noc, J. J. Piek, J. Pirk, Y. Rozenman, M. Sabate, R. Starc, M. Thielmann, D. J. Wheatley, S. Windecker, M. Zembala. (2010) Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 31:20, 2501-2555
    CrossRef

  31. 31

    Hans-Richard Arntz, Leo L. Bossaert, Nicolas Danchin, Nikolaos I. Nikolaou. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation 81:10, 1353-1363
    CrossRef

  32. 32

    Jerry P. Nolan, Jasmeet Soar, David A. Zideman, Dominique Biarent, Leo L. Bossaert, Charles Deakin, Rudolph W. Koster, Jonathan Wyllie, Bernd Böttiger. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation 81:10, 1219-1276
    CrossRef

  33. 33

    F. Borgia, S. G. Goodman, S. Halvorsen, W. J. Cantor, F. Piscione, M. R. Le May, F. Fernandez-Aviles, P. L. Sanchez, K. Dimopoulos, B. Scheller, P. W. Armstrong, C. Di Mario. (2010) Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. European Heart Journal 31:17, 2156-2169
    CrossRef

  34. 34

    Alex Hobson, Nick Curzen. 2010. Acute Coronary Syndromes and Myocardial Infarction. , 234-255.
    CrossRef

  35. 35

    Paul W. Armstrong, Anthony Gershlick, Patrick Goldstein, Robert Wilcox, Thierry Danays, Erich Bluhmki, Frans Van de Werf. (2010) The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. American Heart Journal 160:1, 30-35.e1
    CrossRef

  36. 36

    Marco Tubaro. (2010) An organized system of emergency care for patients with myocardial infarction: a reality?. Future Cardiology 6:4, 483-489
    CrossRef

  37. 37

    Freek WA Verheugt. (2010) Timing of angiography after fibrinolysis for ST-elevation acute myocardial infarction. Current Opinion in Cardiology 25:4, 302-304
    CrossRef

  38. 38

    Kazuo Kimura, Masami Kosuge, Jyun Okuda. (2010) Percutaneous coronary intervention in ST-segment elevation myocardial infarction. Cardiovascular Intervention and Therapeutics 25:2, 53-59
    CrossRef

  39. 39

    Young-Jo Kim. (2010) Reperfusion Strategies in Acute ST-segment Elevation Myocardial Infarction. Journal of the Korean Medical Association 53:3, 196
    CrossRef

  40. 40

    Hanne Beltesbrekke, Mari Husa, Harald Vik-Mo. (2010) Akutt hjerteinfarkt i Midt-Norge – transport for primær PCI-behandling eller trombolyse?. Tidsskrift for Den norske legeforening 130:17, 1714-1716
    CrossRef

  41. 41

    Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Alice K. Jacobs, Judith S. Hochman, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Catheterization and Cardiovascular Interventions 74:7, E25-E68
    CrossRef

  42. 42

    Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Judith S. Hochman, Alice K. Jacobs, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Journal of the American College of Cardiology 54:23, 2205-2241
    CrossRef

  43. 43

    Deepak Thomas, Robert P. Giugliano. (2009) Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. American Heart Journal 158:5, 695-705
    CrossRef

  44. 44

    Amit Kumar, Christopher P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part II. Mayo Clinic Proceedings 84:11, 1021-1036
    CrossRef

  45. 45

    Nicolas Danchin. (2009) Systems of Care for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 2:10, 901-908
    CrossRef

  46. 46

    Michael A. Morse, Josh W. Todd, George A. Stouffer. (2009) Optimizing the Use of Thrombolytics in ST-Segment Elevation Myocardial Infarction. Drugs 69:14, 1945-1966
    CrossRef

  47. 47

    Allan M. Ross, Kurt Huber, Uwe Zeymer, Paul W. Armstrong, Christopher B. Granger, Patrick Goldstein, Kris Bogaerts, Frans Van de Werf. (2009) The Impact of Place of Enrollment and Delay to Reperfusion on 90-Day Post-Infarction Mortality in the ASSENT-4 PCI Trial. JACC: Cardiovascular Interventions 2:10, 925-930
    CrossRef

  48. 48

    John Kanakakis, John N. Nanas, Eleftheria P. Tsagalou, George D. Maroulidis, Stavros G. Drakos, Argirios S. Ntalianis, Panagiotis Tzoumele, Emmanuel Skoumbourdis, Panagiotis Charbis, Stylianos Rokas, Maria Anastasiou-Nana. (2009) Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: The Athens PCI trial. Catheterization and Cardiovascular Interventions 74:3, 398-405
    CrossRef

  49. 49

    Rohit Seth Loomba, Rohit Arora. (2009) ST Elevation Myocardial Infarction Guidelines Today: A Systematic Review Exploring Updated ACC/AHA STEMI Guidelines and Their Applications. American Journal of Therapeutics 16:5, e7-e13
    CrossRef

  50. 50

    Olivier F. Bertrand, Josep Rodés-Cabau, Éric Larose, Can Manh Nguyen, Jean-Pierre Déry, Guy Proulx, Louis Roy, Paul Poirier, Olivier Costerousse, Robert De Larochellière. (2009) Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial. International Journal of Cardiology 136:2, 165-170
    CrossRef

  51. 51

    Amanda Carver, Suzanne Rafelt, Anthony H. Gershlick, Kathryn L. Fairbrother, Sarah Hughes, Robert Wilcox. (2009) Longer-Term Follow-Up of Patients Recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) Trial. Journal of the American College of Cardiology 54:2, 118-126
    CrossRef

  52. 52

    Gjin Ndrepepa, Albert Schömig, Adnan Kastrati. (2009) The Only Better Alternative to Rescue Percutaneous Coronary Intervention Is Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology 54:2, 127-129
    CrossRef

  53. 53

    Verheugt, Freek W.A., . (2009) Routine Angioplasty after Fibrinolysis — How Early Should “Early” Be?. New England Journal of Medicine 360:26, 2779-2781
    Full Text

  54. 54

    N. Danchin, R. Carda, A. Chaib, A. Lepillier, E. Durand. (2009) Optimizing outcomes in patients with STEMI: mortality, bleeding, door-to-balloon times, and guidelines: the approach to regional systems for STEMI care: defining the ideal approach to reperfusion therapy based on recent trials. European Heart Journal Supplements 11:Suppl C, C25-C30
    CrossRef

  55. 55

    Cheuk-Kit Wong, Harvey D. White. 2009. Fibrinolysis for Acute Myocardial Infarction. , 651-666.
    CrossRef

  56. 56

    (2009) Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Revista Española de Cardiología 62:3, 293.e1-293.e47
    CrossRef

  57. 57

    Henry E. Wang, Oscar C. Marroquin, Kenneth J. Smith. (2009) Direct Paramedic Transport of Acute Myocardial Infarction Patients to Percutaneous Coronary Intervention Centers: A Decision Analysis. Annals of Emergency Medicine 53:2, 233-240.e5
    CrossRef

  58. 58

    Sofiene Rekik, Sabeur Mnif, Mohammed Sahnoun, Salma Krichen, Hanene Charfeddine, Imen Trabelsi, Faten Triki, Mourad Hentati, Samir Kammoun. (2009) Total absence of ST-segment resolution after failed thrombolysis is correlated with unfavorable short- and long-term outcomes despite successful rescue angioplasty. Journal of Electrocardiology 42:1, 73-78
    CrossRef

  59. 59

    Nevio Taglieri, Carlo Di Mario. (2009) Percutaneous coronary intervention following thrombolysis: For whom and when?. Acute Cardiac Care 11:4, 195-203
    CrossRef

  60. 60

    D. Dudek, T. Rakowski, A. Dziewierz, P. Kleczynski. (2008) PCI after lytic therapy: when and how?. European Heart Journal Supplements 10:Suppl J, J15-J20
    CrossRef

  61. 61

    William E Boden, Vipul Gupta. (2008) Reperfusion strategies in acute ST-segment elevation myocardial infarction. Current Opinion in Cardiology 23:6, 613-619
    CrossRef

  62. 62

    , F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P. G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , S. Silber, F. V. Aguirre, N. Al-Attar, E. Alegria, F. Andreotti, W. Benzer, O. Breithardt, N. Danchin, C. D. Mario, D. Dudek, D. Gulba, S. Halvorsen, P. Kaufmann, R. Kornowski, G. Y. H. Lip, F. Rutten. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. European Heart Journal 29:23, 2909-2945
    CrossRef

  63. 63

    Charles V. Pollack, Elliott M. Antman, Judd E. Hollander. (2008) 2007 Focused Update to the ACC/AHA Guidelines for the Management of Patients With ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice. Annals of Emergency Medicine 52:4, 344-355.e1
    CrossRef

  64. 64

    Jeffrey A. Tabas, Robert M. Rodriguez, Hilary K. Seligman, Nora F. Goldschlager. (2008) Electrocardiographic Criteria for Detecting Acute Myocardial Infarction in Patients With Left Bundle Branch Block: A Meta-analysis. Annals of Emergency Medicine 52:4, 329-336.e1
    CrossRef

  65. 65

    David M. Larson, Timothy D. Henry. (2008) Reperfusion options in ST-elevation myocardial infarction patients with expected delays. Current Cardiology Reports 10:5, 415-423
    CrossRef

  66. 66

    Harvey D White, Derek P Chew. (2008) Acute myocardial infarction. The Lancet 372:9638, 570-584
    CrossRef

  67. 67

    Robin M. Naples, James W. Harris, Chris A. Ghaemmaghami. (2008) Critical Care Aspects in the Management of Patients with Acute Coronary Syndromes. Emergency Medicine Clinics of North America 26:3, 685-702
    CrossRef

  68. 68

    Rik Hermanides, Jan Paul Ottervanger. (2008) Treatment of ST-elevation myocardial infarction. Future Cardiology 4:4, 391-397
    CrossRef

  69. 69

    J. Matthew Brennan, John L. Petersen. (2008) Early intervention: Which patients and how early?. Current Cardiology Reports 10:4, 303-311
    CrossRef

  70. 70

    H.-R. Arntz. (2008) Reperfusion strategies in ST-elevation myocardial infarction—Current status and perspectives for early and pre-hospital treatment. Resuscitation 77:3, 296-305
    CrossRef

  71. 71

    George Dangas, Gregg W. Stone, Mitchell D. Weinberg, John Webb, David A. Cox, Bruce R. Brodie, Mitchell W. Krucoff, Raymond J. Gibbons, Alexandra J. Lansky, Roxana Mehran. (2008) Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: Comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). American Heart Journal 155:6, 1090-1096
    CrossRef

  72. 72

    Darryn L. Appleton, Antonio Abbate, Giuseppe G.L. Biondi-Zoccai. (2008) Late percutaneous coronary intervention for the totally occluded infarct-related artery: A meta-analysis of the effects on cardiac function and remodeling. Catheterization and Cardiovascular Interventions 71:6, 772-781
    CrossRef

  73. 73

    Luc Lorgis, Marianne Zeller, Gilles Dentan, Yves Laurent, Jamal Abou Taam, Isabelle L'Huillier, Michel Vincent-Martin, Hamid Makki, Yves Cottin, . (2008) Prognostic value of ST-segment resolution after rescue percutaneous coronary intervention. Data from the RICO survey. Catheterization and Cardiovascular Interventions 71:5, 607-612
    CrossRef

  74. 74

    Turgay Celik, Atila Iyisoy, Murat Celik, U.Cagdas Yuksel, Ersoy Isik. (2008) The safety and effectiveness of rescue percutaneous coronary intervention for failed thrombolysis in older population. International Journal of Cardiology 125:2, 288-289
    CrossRef

  75. 75

    Nicholas J. Alp, Anthony H. Gershlick, Amanda Carver, Suzanne E. Stevens, Robert Wilcox. (2008) Rescue angioplasty for failed thrombolysis in older patients: Insights from the REACT trial. International Journal of Cardiology 125:2, 254-257
    CrossRef

  76. 76

    Damian J. Kelly, Anthony H. Gershlick. 2008. Rescue PCI. , 118-135.
    CrossRef

  77. 77

    Giuseppe De Luca, Harry Suryapranata, Paolo Marino. (2008) Reperfusion Strategies in Acute ST-Elevation Myocardial Infarction: An Overview of Current Status. Progress in Cardiovascular Diseases 50:5, 352-382
    CrossRef

  78. 78

    Robert C Welsh, Paul W Armstrong. 2008. Treatment Opportunities with Fibrinolytic Therapy. , 71-90.
    CrossRef

  79. 79

    Antonio Abbate, Giuseppe G.L. Biondi-Zoccai, Darryn L. Appleton, Paul Erne, Andreas W. Schoenenberger, Michael J. Lipinski, Pierfrancesco Agostoni, Imad Sheiban, George W. Vetrovec. (2008) Survival and Cardiac Remodeling Benefits in Patients Undergoing Late Percutaneous Coronary Intervention of the Infarct-Related Artery. Journal of the American College of Cardiology 51:9, 956-964
    CrossRef

  80. 80

    Michael W. Rich. 2008. Therapy of Acute Myocardial Infarction. , 293-326.
    CrossRef

  81. 81

    Nicolas Danchin, Paul W Armstrong. (2008) PCI at non-PCI centres: immediate or rescue?. The Lancet 371:9612, 534-536
    CrossRef

  82. 82

    B. K. Goyal. (2008) To rescue or not?. Catheterization and Cardiovascular Interventions 71:2, 146-146
    CrossRef

  83. 83

    Babu Kunadian, Kunadian Vijayalakshmi, Joel Dunning, Andrew GC Sutton, Douglas F Muir, Robert A Wright, James A Hall, Mark A de Belder. (2008) Rescue angioplasty after failed fibrinolysis foracute myocardial infarction: Predictors of a failed procedure and 1-year mortality. Catheterization and Cardiovascular Interventions 71:2, 138-145
    CrossRef

  84. 84

    Carlo Di Mario, Dariusz Dudek, Federico Piscione, Waldemar Mielecki, Stefano Savonitto, Ernesto Murena, Konstantinos Dimopoulos, Antonio Manari, Achille Gaspardone, Andrzej Ochala, Krzysztof Zmudka, Leonardo Bolognese, Philippe Gabriel Steg, Marcus Flather. (2008) Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. The Lancet 371:9612, 559-568
    CrossRef

  85. 85

    Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
    CrossRef

  86. 86

    Hans OJ Peels, Rutger L Anthonio, Gillian AJ Jessurun, Felix Zijlstra. (2008) Mechanical intervention after thrombolysis. Journal of Cardiovascular Medicine 9:1, 15-21
    CrossRef

  87. 87

    Christopher E. Buller, Robert C. Welsh, Cynthia M. Westerhout, John G. Webb, Blair O'Neill, Richard Gallo, Paul W. Armstrong. (2008) Guideline adjudicated fibrinolytic failure: Incidence, findings, and management in a contemporary clinical trial. American Heart Journal 155:1, 121-127
    CrossRef

  88. 88

    Elliott M. Antman, Mary Hand, Paul W. Armstrong, Eric R. Bates, Lee A. Green, Lakshmi K. Halasyamani, Judith S. Hochman, Harlan M. Krumholz, Gervasio A. Lamas, Charles J. Mullany, David L. Pearle, Michael A. Sloan, Sidney C. Smith. (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 51:2, 210-247
    CrossRef

  89. 89

    (2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
    CrossRef

  90. 90

    James J.H. Chong, Anand N. Ganesan, Vicki Eipper, Pramesh Kovoor. (2008) Comparison of Left Ventricular Ejection Fraction and Inducible Ventricular Tachycardia in ST-Elevation Myocardial Infarction Treated by Primary Angioplasty Versus Thrombolysis. The American Journal of Cardiology 101:2, 153-157
    CrossRef

  91. 91

    Xavier Armoiry, Xavier Dode, Éric Bonnefoy, Gilles Aulagner, François Gimenez†, Éric François. 2008. Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. , 127-155.
    CrossRef

  92. 92

    Theodore D. Fraker, Stephan D. Fihn. (2007) 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina. Journal of the American College of Cardiology 50:23, 2264-2274
    CrossRef

  93. 93

    J.-P. Collet, F. Beygui, O. Barthélemy, B. Livarek, G. Montalescot. (2007) Traitement du thrombus dans les syndromes coronaires aigus en salle de cardiologie interventionnelle. Annales de Cardiologie et d'Angéiologie 56:6, 250-256
    CrossRef

  94. 94

    Gregory B. Schnell, Albert J. Kryski, Luana Mann, Todd J. Anderson, Israel Belenkie. (2007) Contrast echocardiography accurately predicts myocardial perfusion before angiography during acute myocardial infarction. Canadian Journal of Cardiology 23:13, 1043-1048
    CrossRef

  95. 95

    Daniel E Hilleman, James P Tsikouris, A. Allen Seals, Jonathan D Marmur. (2007) Fibrinolytic Agents for the Management of ST-Segment Elevation Myocardial Infarction. Pharmacotherapy 27:11, 1558-1570
    CrossRef

  96. 96

    Nicholas L.M. Cruden, Chun H. Teh, Ian R. Starkey, David E. Newby. (2007) Reduced vascular complications and length of stay with transradial rescue angioplasty for acute myocardial infarction. Catheterization and Cardiovascular Interventions 70:5, 670-675
    CrossRef

  97. 97

    María J. Pérez-Vizcayno, Rosa A. Hernández-Antolín, Fernando Alfonso, Camino Bañuelos de Lucas, Javier Escaned, Pilar Jiménez, Antonio Fernández-Ortiz, Cristina Fernández, Carlos Macaya. (2007) Evolución en los últimos 20 años en el perfil demográfico, epidemiológico y clínico, técnica y resultados de los procedimientos coronarios percutáneos. Revista Española de Cardiología 60:9, 932-942
    CrossRef

  98. 98

    William E. Boden, Kim Eagle, Christopher B. Granger. (2007) Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:10, 917-929
    CrossRef

  99. 99

    Richard J. Gumina. (2007) New Trials and Therapies for Acute Myocardial Infarction. Medical Clinics of North America 91:4, 729-749
    CrossRef

  100. 100

    E. V. Gelfand, C. P. Cannon. (2007) Myocardial infarction: contemporary management strategies. Journal of Internal Medicine 262:1, 59-77
    CrossRef

  101. 101

    Babu Kunadian, Andrew G.C. Sutton, Kunadian Vijayalakshmi, Andrew R. Thornley, Janine C. Gray, Ever D. Grech, James A. Hall, Alun A. Harcombe, Robert A. Wright, Roger H. Smith, Jerry J. Murphy, Ananthaiah Shyam-Sundar, Michael J. Stewart, Adrian Davies, Nicholas J. Linker, Mark A. de Belder. (2007) Early invasive versus conservative treatment in patients with failed fibrinolysis—no late survival benefit: The final analysis of the Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) randomized trial. American Heart Journal 153:5, 763-771
    CrossRef

  102. 102

    José G. Galache Osuna, Cristina Moreno Ambroj, Juan Sánchez-Rubio Lezcano, Isabel Calvo Cebollero, Ana Portolés Ocampo, Carmen Aured Guallar, Jose A. Diarte de Miguel, Luis J. Placer Peralta. (2007) Evolución a corto y medio plazo del infarto agudo de miocardio transmural en mujeres ancianas. ¿Son tratadas correctamente?. Revista Española de Geriatría y Gerontología 42:3, 142-148
    CrossRef

  103. 103

    (2007) Door-to-Balloon Time in Acute Myocardial Infarction. New England Journal of Medicine 356:14, 1475-1479
    Full Text

  104. 104

    Mohsin Farooq, Amer S Qureshi, Iain B Squire. (2007) Early management of ST elevation myocardial infarction: a review of practice. Expert Opinion on Pharmacotherapy 8:4, 401-413
    CrossRef

  105. 105

    W. Frank Peacock, Judd E. Hollander, Richard W. Smalling, Michael J. Bresler. (2007) Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction. The American Journal of Emergency Medicine 25:3, 353-366
    CrossRef

  106. 106

    Rishi Gupta, Tudor G Jovin. (2007) Endovascular management of acute ischemic stroke: advances in patient and treatment selection. Expert Review of Neurotherapeutics 7:2, 143-153
    CrossRef

  107. 107

    (2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
    CrossRef

  108. 108

    B.J. Gersh. (2007) Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction. Yearbook of Cardiology 2007, 213-215
    CrossRef

  109. 109

    W.H. Frishman. (2007) Coronary Intervention for Persistent Occlusion after Myocardial Infarction. Yearbook of Medicine 2007, 347-350
    CrossRef

  110. 110

    Harindra C. Wijeysundera, Ram Vijayaraghavan, Brahmajee K. Nallamothu, JoAnne M. Foody, Harlan M. Krumholz, Christopher O. Phillips, Amir Kashani, John J. You, Jack V. Tu, Dennis T. Ko. (2007) Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction. Journal of the American College of Cardiology 49:4, 422-430
    CrossRef

  111. 111

    Ellen Bøhmer, Harald Arnesen, Michael Abdelnoor, Arild Mangschau, Pavel Hoffmann, Sigrun Halvorsen. (2007) The NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction (NORDISTEMI). Scandinavian Cardiovascular Journal 41:1, 32-38
    CrossRef

  112. 112

    Rosa Ana Hernández Antolín, Felipe Fernández-Vázquez, José Moreu Burgos, Ramón López Palop. (2007) Cardiología intervencionista 2006. Revista Española de Cardiología 60, 19-32
    CrossRef

  113. 113

    Shigemasa Tani, Ken Nagao, Ikuyoshi Watanabe, Kimio Kikushima, Kazuhiro Watanabe, Takeo Anazawa, Hirofumi Kawamata, Eizo Tachibana, Michiaki Matsumoto, Takamichi Kumabe, Katsuo Kanmatsuse, Toshio Kushiro. (2007) Increasingly Well-Preserved Left Ventricular Function in Hospital Survivors With Acute Myocardial Infarction. Circulation Journal 71:2, 180-185
    CrossRef

  114. 114

    Justin A. Ezekowitz, Pierre Théroux, Robert Welsh, Iqbal Bata, John Webb, Paul W. Armstrong. (2007) Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?This paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.. Canadian Journal of Physiology and Pharmacology 85:1, 173-178
    CrossRef

  115. 115

    Cesar E. Mendoza, Mehul R. Bhatt, Salim Virani, Alan H. Schob, Stewart Levine, Alexandre C. Ferreira, Eduardo de Marchena. (2007) Management of failed thrombolysis after acute myocardial infarction: An overview of current treatment options. International Journal of Cardiology 114:3, 291-299
    CrossRef

  116. 116

    Jean-Philippe Collet, Gilles Montalescot, Michel Le May, Maria Borentain, Anthony Gershlick. (2006) Percutaneous Coronary Intervention After Fibrinolysis. Journal of the American College of Cardiology 48:7, 1326-1335
    CrossRef

  117. 117

    Henry J Mann, Paul E Nolan. (2006) Update on the management of cardiogenic shock. Current Opinion in Critical Care 12:5, 431-436
    CrossRef

  118. 118

    Dean J. Kereiakes, Elliott M. Antman. (2006) Clinical Guidelines and Practice. Journal of the American College of Cardiology 48:6, 1129-1135
    CrossRef

  119. 119

    V. Wenzel, S. Russo, H. R. Arntz, J. Bahr, M. A. Baubin, B. W. Böttiger, B. Dirks, V. Dörges, C. Eich, M. Fischer, B. Wolcke, S. Schwab, W. G. Voelckel, H. W. Gervais. (2006) Die neuen Reanimationsleitlinien 2005 des European Resuscitation Council. Der Anaesthesist 55:9, 958-979
    CrossRef

  120. 120

    Hendrik-Jan Dieker, Elvira V. Horssen, Ferry M. R. J. Hersbach, Marc A. Brouwer, Ad J. Boven, Arnoud W. J. Hof, Wim R. M. Aengevaeren, Freek W. A. Verheugt, Frits W. H. M. Bär. (2006) Transport for abciximab facilitated primary angioplasty versus on-site thrombolysis with a liberal rescue policy: the randomised Holland Infarction Study (HIS). Journal of Thrombosis and Thrombolysis 22:1, 39-45
    CrossRef

  121. 121

    (2006) Rescue Angioplasty after Thrombolysis. New England Journal of Medicine 354:15, 1639-1641
    Full Text

  122. 122

    Simon R. Dixon, Cindy L. Grines, William W. O’Neill. (2006) The Year in Interventional Cardiology. Journal of the American College of Cardiology 47:8, 1689-1706
    CrossRef

  123. 123

    Gregg W Stone, Bernard J Gersh. (2006) Facilitated angioplasty: paradise lost. The Lancet 367:9510, 543-546
    CrossRef

  124. 124

    Kazuyuki Shirai, Keijiro Saku. (2006) Treatment Strategy for Patients with Acute Myocardial Infarction. Internal Medicine 45:13, 807-808
    CrossRef

Letters